Having trouble viewing this email? View in your browser.

This email contains promotional information from Tillotts Pharma.
Prescribing information can be found via a link at the bottom of this email.

Tillotts Pharma invite you to join them at their promotional stand at the upcoming ECCMID 2021 Congress!

On our stand you can find out more information about our recently acquired first-line treatment option for Clostridioides difficile infection (CDI), DIFICLIR.

A narrow-spectrum macrocyclic anti-bacterial agent, DIFICLIR is available as film-coated tablets. It is indicated for the treatment of CDI, also known as C. difficile-associated diarrhoea (CDAD), in adults and paediatric patients with a body weight of at least 12.5 kg.1

DIFICLIR is an exciting product addition for Tillotts, as it fits into our existing GI portfolio, increasing our potential to help even more patients. Using DIFICLIR to treat CDI is already known to reduce recurrence rates more than vancomycin,2,3 with DIFICLIR showing associated hospital cost-savings versus vancomycin.4,5

Ultimately, our aim is to help you achieve the best possible outcomes for your patients and your hospital, particularly when treating the elderly, cancer patients and others with weakened immune systems.

GI: gastrointestinal
1. DIFICLIR (fidaxomicin), Summary of Product Characteristics.
2. Louie TJ, et al. N Engl J Med 2011;364:422–31
3. Cornely OA, et al. Lancet Infect Dis 2012;12:281–9
4. Watt M, et al. Infection. 2016;44(5):599–606
5. Watt M, et al. J Med Econ. 2017;20(7):678–686

Click here for prescribing information

Adverse events should be reported.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.